Skip to main content
SpringerLink
Log in

Die aktuelle Studienlage

Cannabis bei Krebserkrankungen

Cannabis and cancer

  • FB_Übersicht
  • Published:
MMW - Fortschritte der Medizin Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

© F. Grotenhermen

Abb. 2

© F. Grotenhermen

Abb. 3

© F. Grotenhermen

Abb. 4

© F. Grotenhermen

Author information

Authors and Affiliations

  1. Zentrum für Cannabismedizin, Bahnhofsallee 9, 32839, Steinheim, Germany

    Franjo Grotenhermen

Authors
  1. Franjo Grotenhermen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Franjo Grotenhermen.

Ethics declarations

Ich habe von folgenden Firmen Honorare für Beratung oder Vorträge erhalten: Bionorica SE, Canify A/S , Demecan Holding GmbH, Drapalin Pharmaceuticals GmbH , Four 20 Pharma GmbH, GECA Pharma GmbH, Heyday AG, Medican Pharma GmbH, MYCB1, Nature Bloom GmbH, Oxygen Handel GmbH, Spectrum Therapeutics GmbH, STADA Arzneimittel AG, Storz & Bickel GmbH & Co. KG, Swiss Organic Partners AG, THC Pharm GmbH, Vayamed GmbH, Telaleaf Health

Supplementary Information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Grotenhermen, F. Cannabis bei Krebserkrankungen. MMW - Fortschritte der Medizin 164 (Suppl 5), 26–29 (2022). https://doi.org/10.1007/s15006-022-1854-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-022-1854-3

Keywords:

Search

Navigation